Regenerative Protein Arrays (RPA)

RPA works by “reprogramming” the local environment, reactivating the cellular processes, and returning the body to the homeostasis of pre-puberty, the peak of the body’s ability to heal.

• Regenerative Protein Array (RPA) is only sourced from donors with a 20-year history of no cancer, no systemic disease, and no genetic altering therapies or inoculations (i.e. COVID-19 Vaccination.)

• All donors are screened with lifestyle testing and proven negative for communicable disease via third party, FDA/CLIA certified labs.

• Post-incubation, the product goes through a 4-stage filtering process to remove all cellular tissue, yielding the acellular, non-biologic product you know as RPA.

• The final stage before lyophilization is endotoxin testing, where third party, FDA/CLIA certified labs prove the final product to be “sterile” via meeting the minimum standard of <0.005 EU/mL.

• RPA is produced at FDA registered labs in the United States.

• All donors, tissue, and final product are tested at third party FDA/CLIA certified labs.

• The FDA classifies RPA as a “cell factor” since it is created through an incubation / emission process and is acellular. Therefore, the product is exempt from 21 CFR 1271 biologic regulations.

• The FDA oversees all steps of donation, transport, testing, production, sterilization, and packaging, but treats RPA like a nutraceutical, leaving the choice of use up to the treating physician and patient.